We have one on the board who is vice chairman of Novo Nordisk A/S, aswell as another director who is the retiring senior vice president of the Biopharmaceuticals Research Unit at Novo Nordisk , plus another who was a senior Vice president of Pfizer.
Has to be one of the kost qualified boards in Australia, the other board members are extremely impressive aswell.
Dr G?ran Ando Non-executive Director
Dr G?ran Ando is the former Executive Vice President and President of Research & Development of Pharmacia Corporation which was acquired by Pfizer Inc. in 2003. In April 2003, he accepted the appointment as Chief Executive Officer with CellTech Group PLC in the United Kingdom until its acquisition in 2004 by UCB. Dr Ando is currently Chairman of Novexel SA, Paris, Vice Chairman of Novo Nordisk A/S, Copenhagen, and Vice Chairman of S*Bio Pty Ltd, Singapore. In addition, Dr Ando is presently a Member of the Board of Directors of the following companies: Novo A/S, Copenhagen, Nicox SA, France, EUSA Pharma, United Kingdom, Bio*One Capital Pte Ltd, Singapore, CBio Ltd, Brisbane and Albea Pharmaceuticals AG, Switzerland. Dr Ando also serves as a Senior Advisor to Essex Woodlands Health Ventures UK Ltd.
In addition, Dr Ando is Chairman of the Scientific Advisory Board, Southwest Michigan First (SWMF).
Dr Ando is a Specialist in General Medicine and is a Founding Fellow of the American College of Rheumatology in the US.
Peter Corr, PhD. Non-executive Director
Peter B. Corr, PhD., is General Partner, Celtic Therapeutics Management Company L.L.L.P., a private equity firm focused on the development of innovative therapeutics, alliances that advance solutions for diseases of the developing world, and global advocacy for biomedical innovation. Dr. Corr retired from Pfizer Inc in 2007, where he served as Senior Vice President, Science & Technology. Previously, he was Executive Vice President, Pfizer Global Research & Development, and President, Worldwide Development. Prior, Dr. Corr was President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis until the merger with Pfizer) and he previously served as Senior Vice President, Discovery Research, at Monsanto/Searle.
Terje Kalland Non-executive Director
Dr Terje Kalland, MD, PhD, is a former professor of tumour immunology and has served 22 years in the pharmaceutical industry. He is the retiring senior vice president of the Biopharmaceuticals Research Unit at Novo Nordisk. His leadership has been with a focus on discovery and preclinical development, and he also has experience in phase I/II clinical development. He has brought more than 40 large and small molecule-based drug candidates into development.
Prior to his appointment at Novo Nordisk, Dr Kalland was Chief Scientific Officer at Biovitrium AB in Stockholm, Sweden. From 1988 to 2001, he worked at Pharmacia, where he spent the last seven years of his appointment as the global head of Oncology Research.
Dr Thomas L?nngren Non-executive Director
Dr Thomas L?nngren served as the Executive Director of the European Medicines Agency (EMEA) from 2001 through to his retirement in December 2010. He qualified as a pharmacist from the University of Uppsala in 1976 and holds as MSc in social and regulatory pharmacy. From 1976-78 he was a lecturer at Uppsala University, Sweden.
He served with the Swedish National Board of Health and Welfare from 1976-90 with responsibilities including herbal medicines, cosmetics, medical devices, narcotics and contraceptives. During 1982-94 he acted as senior pharmaceutical consultant for the Swedish International Development Agency?s health cooperation programme in Vietnam. In 1990 he was appointed Director of Operations of the Swedish Medical Products Agency, later becoming Deputy Director-General of the Agency.
He was an Honorary Member of the Royal Pharmaceutical Society of Great Britain in 2003 and made an Honorary Fellow of the Royal College of Physicians in 2004. He was granted an Honorary Doctorate from the University of Uppsala in and received Drug Information Associations Distinguished Career Award in 2008.
CBZ Price at posting:
57.4¢ Sentiment: Buy Disclosure: Held
